Clinical trials: Acute Migraine
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.
- Trial name
- ACHIEVE I (NCT02828020)
- Testing
- Ubrogepant
- Where
- 90 sites in United States
- Volunteers
- 1,672 people
- Sponsor
- Allergan
Migraine With Aura, Migraine Without Aura
Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
The primary objective of this study is to evaluate the efficacy and safety of dronabinol MDI for the acute treatment of moderate to severe migraine headache.
- Trial name
- NCT00123201
- Testing
- Dronabinol MDI
- Where
- 29 sites in United States
- Sponsor
- Solvay Pharmaceuticals
Migraine
An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine
The purpose of this protocol is to allow subjects who completed any BHV3000 (rimegepant) clinical study to continue to have access to rimegepant while collecting ongoing safety data.
- Trial name
- NCT03934086
- Testing
- rimegepant
- Sponsor
- Pfizer
Headache (Migraine)
Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine.
To determine whether a single dose of intravenous lornoxicam is superior to intravenous placebo for the acute treatment of moderate or severe headache associated with a single migraine attack in patients with a history of…
- Trial name
- NCT00293657
- Testing
- Lornoxicam 8 mg, Lornoxicam 16 mg
- Where
- 23 sites in United States
- Volunteers
- 150 people
- Sponsor
- POZEN
Migraine, With or Without Aura
Open Label Safety Study in Acute Treatment of Migraine
The purpose of this study is to evaluate safety and tolerability of BHV-3000 (rimegepant).
- Trial name
- NCT03266588
- Testing
- Rimegepant
- Where
- 98 sites in United States
- Volunteers
- 3,019 people
- Sponsor
- Pfizer
Migraine
A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.
The purpose of this study is to collect information of the US users from the Migraine Buddy app between 20 October 2023 and 20 May 2024.
- Trial name
- NCT06532357
- Where
- United States
- Volunteers
- 1,536 people
- Sponsor
- Pfizer
Migraine
Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)
The purpose of this study is to test the effectiveness of rizatriptan benzoate in the early treatment of an acute migraine attack.
- Trial name
- NCT00516737
- Testing
- Comparator: rizatriptan benzoate
- Volunteers
- 207 people
- Sponsor
- Organon and Co
Migraine
A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)
The purpose of this study is to assess the effectiveness, safety and tolerability of a range of doses of MK-1602 versus placebo in the treatment of acute migraine.
- Trial name
- NCT01613248
- Testing
- MK-1602, Rescue medication
- Volunteers
- 834 people
- Sponsor
- Allergan
Acute Migraine
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)
A study to provide evidence supporting the benefit of Rizatriptan in patients who have an inadequate response to sumatriptan.
- Trial name
- NCT00894556
- Testing
- rizatriptan, Comparator: Sumatriptan
- Volunteers
- 109 people
- Sponsor
- Organon and Co
Acute Migraine
Chordate System S020 Acute Migraine Clinical Investigation
The main purpose of the study is to evaluate the impact of treatment with the Chordate System S020 (medical device) on acute migraine headache pain.
- Trial name
- Amici (NCT02185703)
- Testing
- Chordate System S020 in treatment mode
- Where
- 9 sites in Germany
- Volunteers
- 51 people
- Sponsor
- Chordate Medical
Migraine Disorders
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
The primary objective is to evaluate the safety of long-term treatment with NP101 as assessed by: Subject self-examination skin irritation scores Adverse events Changes in vital signs and ECG parameters The secondary objective is…
- Trial name
- NP101-008 (NCT00792103)
- Testing
- NP101
- Where
- 34 sites in United States
- Volunteers
- 198 people
- Sponsor
- NuPathe Inc.
Acute Migraine
Safety and Efficacy of Nerivio™ for the Acute Treatment of Migraine in Adolescents
Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine.
- Trial name
- NCT04089761
- Testing
- Nerivio
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Theranica
Migraine
RCT of Non-Invasive Vagus Nerve Stimulation (nVNS) With gammaCore®, for the Acute Treatment of Migraine Attacks
This study is a prospective, multi-centre, randomised, double-blind, sham-controlled investigation designed for comparison of two parallel treatment groups: gammaCore (active nVNS treatment) and a Sham device (control treatment)…
- Trial name
- NCT02686034
- Testing
- gammaCore-S
- Where
- 10 sites in Italy
- Volunteers
- 285 people
- Sponsor
- ElectroCore INC
Migraine, With or Without Aura
Trial in Adult Subjects With Acute Migraines
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant ODT) versus placebo in subjects with Acute Migraines.
- Trial name
- NCT03461757
- Testing
- Rimegepant
- Where
- 69 sites in United States
- Volunteers
- 1,811 people
- Sponsor
- Pfizer
Migraine Headaches
The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months
The objective of this study is to assess the safety of a single-tablet dose of Combo Formulation for the treatment of moderate to severe migraines
- Trial name
- NCT00442221
- Testing
- Sumatriptan and Naproxen sodium
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- POZEN
Migraine
Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds
Study Objectives: 1. The primary objective is to characterize the pharmacokinetics of a single oral administration of 50 mg Cambia in pediatric subjects, ages 12-17 years with a diagnosis of episodic migraine with or without…
- Trial name
- NCT02287376
- Testing
- Diclofenac Potassium for Oral Solution
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Depomed
Migraine Disorders
TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine
An evaluation of tablet disintegration and absorption and gastric transit of sumatriptan and naproxen sodium from a TREXIMA tablet and eletriptan from a RELPAX 40mg tablet.
- Trial name
- NCT00385008
- Testing
- Combination Product (sumatriptan succinate / naproxen sodium), RELPAX(eletriptan) 40mg Tablet
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Migraine Headaches
Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine
This is a Phase 1/ Phase 2, 12-week, multi-center, randomized, double-blind, cross-over, placebo-controlled study to evaluate the efficacy and safety of ELS-M11 compared to placebo in 50 male and female subjects, aged 18 to 65…
- Trial name
- NCT02057315
- Testing
- ELS-M11
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Achelios Therapeutics
Acute Migraine
Migraine Treatment With Nerivio Migra Neurostimulation Device
This is a prospective, randomized, double-blind, sham controlled multi-center trial. Ratio between treatment and control groups will be 1:1, stratified by center and use of preventive medications.
- Trial name
- NCT03076515
- Testing
- Nerivio Migra neurostimulation
- Where
- 8 sites in United States, Israel
- Volunteers
- 120 people
- Sponsor
- Theranica
Migraine Disorders, Migraine
An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine
Nitric oxide (NO) is likely to be involved in the development of migraine headache. Nitric oxide synthase (NOS) is an important chemical involved in the production of NO.
- Trial name
- NCT00319137
- Testing
- GW274150
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 126 people
- Sponsor
- GlaxoSmithKline